Molecular Mechanisms of Thymic Epithelial Cell Involution in Aging

衰老过程中胸腺上皮细胞退化的分子机制

基本信息

  • 批准号:
    8129711
  • 负责人:
  • 金额:
    $ 31.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Thymic involution constitutes a hallmark of an aging immune system. The thymus is comprised of thymic epithelial cells (TECs), fibroblasts and blood-borne stromal cells. Adoptive transfers of young and old hematopoietic stem cells into young vs old recipients has led to the conclusion that impaired thymopoiesis in the aged is largely the consequence of an aged thymic microenvironment. TEC differentiation, proliferation, and survival are controlled by cell intrinsic and extrinsic factors. Although much work has been focused on thymus development during embryogenesis, comparatively little is known about the mechanisms responsible for thymic involution. This especially pertains to TECs, which we hypothesize are the major impediment to thymopoiesis during aging. We now propose to fill this critical gap. Our specific aims are: Aim 1: To determine the key transcription factors & signaling pathways in TECs affected by aging. In aim 1A, we will interrogate physiological characteristics of aged vs young TEC subsets. In aim 1B, we hypothesize that key cell surface receptor and intracellular transcriptional pathways that regulate thymic development will be important for TEC maintenance and regeneration after genotoxic stress in aged mice. In aim 1C, we hypothesize that transcriptional regulation by micro-RNAs is an important component of TEC aging. Studies of loss-of-function in TECs alone will be performed in aims 1B and 1C. Aim 2: To test the hypothesis that genetic models of perturbations of the aging process will provide key insights as to the mechanisms responsible for TEC aging. We will identify common features affecting TECs between chronologically aged mice and those with premature aging and distinguishing features in a model of delayed thymic aging. As indicated, drugs that stimulate TECs as probes for assessing residual TEC function in aging.
描述(由申请方提供):胸腺退化是免疫系统老化的标志。胸腺由胸腺上皮细胞(TEC)、成纤维细胞和血源性基质细胞组成。将年轻和老年造血干细胞连续转移到年轻与老年受者中已经得出结论,老年人中受损的胸腺生成在很大程度上是老年胸腺微环境的结果。TEC的分化、增殖和存活受到细胞内在和外在因素的控制。虽然许多工作都集中在胸腺发育在胚胎发生,相对较少的是知道胸腺退化的机制。这特别适用于TEC,我们假设这是衰老过程中胸腺生成的主要障碍。我们现在建议填补这一关键空白。我们的具体目标是:目的1:确定衰老影响TECs的关键转录因子和信号通路。在目标1A中,我们将询问老年与年轻TEC子集的生理特征。在目标1B中,我们假设调节胸腺发育的关键细胞表面受体和细胞内转录途径对老年小鼠遗传毒性应激后TEC的维持和再生至关重要。在目标1C中,我们假设微RNA的转录调控是TEC老化的重要组成部分。将在目标1B和1C中单独进行TEC功能丧失研究。目标二:为了验证这一假设,即衰老过程扰动的遗传模型将为TEC衰老的机制提供关键见解。我们将确定共同的特点,影响TEC之间的时间老化的小鼠和那些过早老化和区别特征的模型延迟胸腺老化。如所指出的,刺激TEC的药物作为用于评估老化中残留TEC功能的探针。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce R Blazar其他文献

Challenges and solutions for cellular therapy development in autoimmune diseases
自身免疫性疾病中细胞治疗发展的挑战与解决方案
  • DOI:
    10.1016/s2665-9913(24)00274-1
  • 发表时间:
    2024-11-01
  • 期刊:
  • 影响因子:
    16.400
  • 作者:
    Elizabeth R Volkmann;John Varga;Bruce R Blazar;Steven Z Pavletic
  • 通讯作者:
    Steven Z Pavletic
Five-Year Outcomes of the “Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease (GVHD) Prophylaxis: A Randomized Controlled Trial” (‘ABA2‘)
  • DOI:
    10.1182/blood-2024-205130
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Lev Gorfinkel;Muna Qayed;Brandi Bratrude;Kayla Betz;Kyle Hebert;Sung W. Choi;Jeffrey Davis;Christine Duncan;Roger H. Giller;Michael S. Grimley;Andrew Harris;David A Jacobsohn;Nahal Lalefar;Nosha Farhadfar;Michael A. Pulsipher;Shalini Shenoy;Aleksandra Petrovic;Kirk R. Schultz;Gregory Yanik;Bruce R Blazar
  • 通讯作者:
    Bruce R Blazar
IL-33 Induces Paneth Cell Production of EGF and Soluble ST2, Regulating Epithelial Regeneration after Intestinal Injury
  • DOI:
    10.1182/blood-2023-191189
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Marco Calafiore;YA-Yuan Fu;Paola Vinci;Viktor Arnhold;Winston Chang;Suze Jansen;Anastasiya Egorova;Shuichiro Takashima;Jason Kuttiyara;Takahiro Ito;Jonathan Serody;Susumu Nakae;Heth Turnquist;Johan van Es;Hans Clevers;Caroline A. Lindemans;Bruce R Blazar;Alan M. Hanash
  • 通讯作者:
    Alan M. Hanash
Cyclosporine and Voclosporin Resistant Immune Effector Cells to Improve Outcomes after Stem Cell Transplantation
  • DOI:
    10.1182/blood-2023-180218
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Holly Wobma;Jiayi Dong;Francesca Alvarez Calderon;Xianliang Rui;Katherine Michaelis;Bruce R Blazar;Victor Tkachev;Ulrike Gerdemann;Leslie Kean
  • 通讯作者:
    Leslie Kean
Mitochondrial Pyruvate Carrier Inhibition Mitigates Murine Chronic Graft Versus Host Disease By Attenuating the Germinal Center Reaction
  • DOI:
    10.1182/blood-2023-185200
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    Fathima A Mohamed;Stephanie Y Rhee;Joanna Ly;Ethan G Aguilar;Haley Melin;Peter T Sage;Tanner Schumacher;Govindarajan Thangavelu;Michael C Zaiken;Juan Liu;Venkatram Mereddy;Jason W Locasale;Bruce R Blazar
  • 通讯作者:
    Bruce R Blazar

Bruce R Blazar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce R Blazar', 18)}}的其他基金

University of Minnesota Clinical and Translational Science Institute (UMN CTSI)
明尼苏达大学临床与转化科学研究所 (UMN CTSI)
  • 批准号:
    10763967
  • 财政年份:
    2023
  • 资助金额:
    $ 31.19万
  • 项目类别:
In Vivo Prevention of Murine GVHD
小鼠 GVHD 的体内预防
  • 批准号:
    10362877
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Metabolomics of cGVHD
cGVHD 的代谢组学
  • 批准号:
    10698171
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
In Vivo Prevention of Murine GVHD
小鼠 GVHD 的体内预防
  • 批准号:
    10610863
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Metabolomics of cGVHD
cGVHD 的代谢组学
  • 批准号:
    10493800
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10560605
  • 财政年份:
    2021
  • 资助金额:
    $ 31.19万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10092348
  • 财政年份:
    2021
  • 资助金额:
    $ 31.19万
  • 项目类别:
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
利用 VISTA 途径预防急性 GVHD 和控制类固醇难治性疾病
  • 批准号:
    10348683
  • 财政年份:
    2021
  • 资助金额:
    $ 31.19万
  • 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
  • 批准号:
    10305635
  • 财政年份:
    2019
  • 资助金额:
    $ 31.19万
  • 项目类别:
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
范可尼贫血基因治疗和同种异体移植的非基因毒性调理
  • 批准号:
    10656502
  • 财政年份:
    2019
  • 资助金额:
    $ 31.19万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 31.19万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 31.19万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 31.19万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 31.19万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 31.19万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 31.19万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 31.19万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 31.19万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 31.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了